Share This Post

Kidney Cancer Drug Shows Promise in Early Trial

From Health Day News

An experimental drug may show promise in treating kidney cancer, researchers say.

The drug CB-839 is the first to target an enzyme that cancer cells require to stay alive, researchers said. This stage 1 clinical trial found that the drug was effective in most patients with advanced kidney cancer when used in combination with another cancer drug called everolimus (Afinitor, Zortress).

Read more here:

Share This Post

Profile photo of Dena Battle
Dena Battle is the President of KCCure. She also serves on the Advisory Board for the Johns Hopkins Sidney Kimmel Cancer Center and as a member of the Patient and Family Advisory Council.

Lost Password


Subscribe for updates!